HPV Vaccine for Laryngeal Papilloma: Does It Reduce Recurrence?
The HPV vaccine for laryngeal papilloma is not a replacement for surgery; in some centres it is used alongside surgery as an add-on (adjuvant) treatment. Two meta-analyses pooling small studies reported fewer operations per year and a longer interval between operations after vaccination.3,4 These results, however, come mostly from retrospective before-and-after comparisons rather than randomised controlled trials.3,7
The vaccine’s second role, prevention, rests on firmer ground. In the United States, juvenile-onset papillomatosis fell sharply in children born after vaccination programmes began.6 This guide covers what the vaccine may offer patients, where the evidence runs out and what to ask your surgeon.
In short
- Why HPV matters: laryngeal papillomas are benign growths caused by HPV types 6 and 11, and surgery is the main treatment.1
- As an add-on in patients: in a meta-analysis of 63 patients, the average interval between operations rose from about 7 months to about 34 months.3
- The evidence is limited: the first meta-analysis included no randomised trial, the evidence comes mostly from retrospective studies, and using the vaccine this way is off-label.3,5,7
- Prevention is stronger: in the US, juvenile-onset disease fell to roughly a quarter in children born in the vaccine era.6
- Other adjuvants: results with drugs such as cidofovir and bevacizumab are mixed or not yet fully proven.1
Papilloma is a viral disease: where does the vaccine fit?
Recurrent respiratory papillomatosis (RRP) is caused by two types of human papillomavirus (HPV), types 6 and 11, and produces benign tumours in the larynx and airway.1 The papillomas can be removed surgically but often grow back; some people need surgery every few weeks, others once a year or less.1 The course of the disease and the surgical options are covered on our vocal fold papilloma treatment page.
Not every HPV vaccine covers types 6 and 11, so it is worth asking your doctor whether a given vaccine protects against them.1 Giving the vaccine to someone who already has papillomas falls outside its licensed use: in the studies, patients received it after agreeing to this off-label use.5
HPV vaccine for laryngeal papilloma: what do the studies show?
A systematic review published in 2019 examined 11 studies with 133 patients, and five studies covering 63 of them were suitable for meta-analysis. The estimated number of operations fell from 0.35 per month before vaccination to 0.06 per month afterwards, and the average interval between operations rose from 7.02 months to 34.45 months.3
A systematic review published in 2023 examined 13 studies with 243 patients in total, but only 62 patients from 4 studies (interval data) and 111 patients from 7 studies (operation counts) could be pooled in the meta-analysis. After vaccination, patients needed on average 4.43 fewer operations per year and the interval between operations was on average 15.73 months longer; the authors concluded that vaccination may be a beneficial adjuvant treatment.4
| Study | Design and patients | Finding |
|---|---|---|
| Rosenberg, 20193 | Systematic review and meta-analysis; 63 patients in the meta-analysis | Interval between operations rose from 7.02 to 34.45 months |
| Ponduri, 20234 | Systematic review (13 studies, 243 patients); 62–111 patients in the meta-analysis | On average 4.43 fewer operations per year; interval on average 15.73 months longer |
| Mauz, 20185 | Retrospective, single centre; 24 patients | Recurrence in 2 of 13 vaccinated patients and in all 11 unvaccinated patients |
How strong is the evidence?
The authors of the first meta-analysis describe their work as a substitute for a multicentre randomised trial that was proposed but never carried out.3
Most studies compare the same patient’s operation rate before and after vaccination. Yet the disease can change course on its own: some children, for example, improve or go into remission around puberty.1 If the disease settles by itself after vaccination, the two effects are hard to separate. In the 24-patient retrospective series, the groups were not randomised either: the vaccine was given to patients who accepted its off-label use.5
In short, the vaccine is an add-on option to discuss in suitable patients, not a substitute for surgery.
| Have your papillomas come back?
Briefly describe your symptoms and how many procedures you have had; if a report or exam finding is needed, we will tell you how to share it.
Prevention: vaccination programmes and juvenile-onset disease
Papillomatosis in children is linked to the virus passing from mother to baby during birth, while in adults it is thought to spread through sexual contact.1
A US study of 576 children from 26 paediatric ENT centres found that the rate fell from 2.0 cases per 100,000 births among children born in 2004–2005 to 0.5 among those born in 2012–2013; the authors judged this most likely due to HPV vaccination.6
The US Centers for Disease Control and Prevention (CDC) recommends routine HPV vaccination at age 11 or 12; it can be started at age 9, and it is recommended for everyone up to age 26 who was not adequately vaccinated when younger. Some adults aged 27 to 45 may decide to be vaccinated after discussion with their clinician. The vaccine is not recommended during pregnancy.2 Schedules differ between countries.
Other adjuvants: cidofovir and bevacizumab
For frequent or hard-to-control disease, other drugs used alongside surgery include antivirals such as interferon and cidofovir, which aim to stop the virus copying itself, and bevacizumab, which targets the blood vessel growth of papillomas. According to the US National Institutes of Health, the results of these and other non-surgical treatments have so far been mixed or not yet fully proven.1
In some centres bevacizumab is given intravenously. Its use in RRP is off-label, and because side effects such as reduced kidney function and high blood pressure can occur, management alongside a medical oncologist is advised.7 In 2024 the AAO-HNS Bulletin reported promising early-phase (phase 1/2) results for therapeutic vaccines aimed at HPV 6 and 11.7 In 2025 the US Food and Drug Administration (FDA) approved an immunotherapy for adults with RRP; this does not mean the treatment is licensed or available in Türkiye, or that it suits every patient.8
Suitability, approval status and availability need specialist assessment; newer immune-directed treatments are described on our vocal fold papilloma page.
What to discuss with your surgeon
Dr. Atmış uses blue laser technology for vocal fold papillomas, aiming to preserve healthy voice tissue at each procedure. Add-on treatments such as a vaccine or a drug do not replace this surgical plan; they are options that may be discussed alongside it. For the role of the laser, see our guide to blue laser treatment for vocal cord lesions.
Useful points to cover: whether you have had an HPV vaccine before, how often you have needed surgery, whether the disease began in childhood or adulthood, and how the vaccine applies at your age. The effect of any add-on treatment can only be judged from a record of the intervals between operations. Our guide to what happens during a laryngoscopy explains how follow-up examinations are done.
Frequently asked questions
Does the HPV vaccine cure laryngeal papilloma?
How effective is the HPV vaccine for laryngeal papilloma?
Can I have the HPV vaccine after being diagnosed with papilloma?
In the studies, the vaccine was given to diagnosed patients as an off-label use.5 Whether it suits you depends on your age and the course of your disease, so discuss it with your doctor.
Does HPV vaccination prevent papilloma in children?
Can I have the HPV vaccine while pregnant?
No. The CDC states that the HPV vaccine is not recommended during pregnancy and that women known to be pregnant should wait until after the pregnancy to start the series.2
Are cidofovir or bevacizumab more effective than the vaccine?
If I am vaccinated, will I never need surgery again?
No evidence guarantees that. Recurrence has also been reported in vaccinated patients, so regular follow-up continues.5
Questions to ask your surgeon
- If I have had an HPV vaccine before, would another one help?
- Could the vaccine be useful at my age and with my pattern of disease?
- How often would I need surgery before an add-on treatment is considered?
- Which records will we use to judge whether an add-on treatment is working?
- When might cidofovir or bevacizumab be discussed for me?
| Let us discuss your papilloma treatment and the add-on options
Briefly describe your symptoms and how many operations you have had; if a report or exam finding is needed, we will tell you how to share it. Add-on options such as the vaccine can be discussed with your surgeon alongside your surgical plan.
Clinical references
- NIDCD (US National Institutes of Health). Recurrent Respiratory Papillomatosis or Laryngeal Papillomatosis.
- Centers for Disease Control and Prevention (CDC). HPV Vaccine Recommendations.
- Rosenberg T, et al. Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. J Infect Dis. 2019;219(7):1016-1025.
- Ponduri A, et al. The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis. Laryngoscope. 2023;133(9):2046-2054.
- Mauz PS, et al. HPV vaccination as preventive approach for recurrent respiratory papillomatosis – a 22-year retrospective clinical analysis. BMC Infect Dis. 2018;18(1):343.
- Meites E, et al. Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States. Clin Infect Dis. 2021;73(5):885-890.
- American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) Bulletin. #WorldVoiceDay: Latest Treatment Advances for RRP.
- US Food and Drug Administration. FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis.
This article is general information, not a personal diagnosis or treatment recommendation. Seek prompt medical care for urgent symptoms.

